The National Nuclear Security Administration (NNSA) today announced that it recovered high-activity radioactive materials from an oncology clinic in Ciudad Juarez, Mexico. NNSA's Global Threat Reduction Initiative (GTRI) and the Mexican ...
Tags: High-activity, radioactive, material, remove, Mexico
According to the National Institutes of Health (NIH), Alzheimer's disease (AD) -- which robs people of the ability to think, remember and reason -- is an irreversible, progressive disease that eventually destroys even the ability to carry ...
Young adults who survived childhood cancer are more likely to be frail and at increased risk of death and chronic disease, U.S. researchers say. Kirsten Ness, an associate member of the St. Jude Department of Epidemiology and Cancer ...
Tags: Cancer Survivors, chronic disease, Medicine
Innate Pharma has started a new program named IPH43, to develop an anti-MICA therapeutic antibody in oncology. The program is the newest to emerge from the company's discovery platform. MICA, which is highly polymorphic ligand of the NK ...
Tags: Innate Pharma, Anti-Mica Antibody
"There is not one, but many cures for cancer available. But they are all being systematically suppressed by ... the major oncology centers. They have too much of an interest in the status quo," stated Dr Robert Atkins, MD, creator of the ...
For its fiscal fourth-quarter 2013 (to 27 September), Skyworks Solutions Inc of Woburn, MA, USA (which manufactures analog and mixed-signal semiconductors) has reported revenue of $477m, up 9.4% on $436.1m last quarter and 13.3% on $421.1m ...
Tags: Electrical, Electronics
US-based Sagent Pharmaceuticals (SGNT) has introduced an antineoplastic agent 'Carboplatin Injection' in four preservative-free vial presentations. The injection is indicated for the initial treatment of advanced ovarian carcinoma in ...
US-based biotechnology firm Ignyta has entered into a license agreement with Nerviano Medical Sciences (Nerviano), under which Ignyta will get exclusive global development and marketing rights of tyrosine kinase inhibitors RXDX-101 and ...
Tags: Ignyta, Tyrosine Kinase Inhibitors
Transgenomic, a global biotechnology company, and US-based PerkinElmer have entered into a collaboration agreement for marketing and distributing Transgenomic’s line of molecular diagnostic oncology products in territories outside the ...
Synta Pharmaceuticals has announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor drug conjugate (HDC) platform, which leverages the company's expertise in chaperone biology and medicinal ...
AstraZeneca has selected an undisclosed oncology target from Regulus Therapeutics as part of their strategic alliance in order to discover, develop and commercialize microRNA therapeutics. Both the companies have entered into a strategic ...
US-based Loxo Oncology has announced that its lead clinical program is a potent and selective inhibitor of the Trk family of receptor tyrosine kinases. Loxo Oncology acquired rights to this program from Array Biopharma, which had pursued ...
Tags: Loxo Oncology, Medicine
Atheris Laboratories and Debiopharm have announced the signature of a collaboration agreement regarding the Atheris 'Reverse-Discovery' lead optimization platform. Collaboration with Atheris is expected to accelerate Debiopharm's ongoing ...
KEW Group, the oncology personalized medicine management and analytics company, has launched CancerPlex assay, a comprehensive gene testing panel that can be used to examine the genetic profile of many common cancers. Developed and ...
Tags: Genomic Testing, Medicine
Eli Lilly and Company has received priority review status from the US Food and Drug Administration (FDA) for its ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial ...
Tags: Cancer Drug, FDA Priority